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This article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed sig-
nificant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined
50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine
nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results
provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.
Standard chemotherapy for the treatment of Toxoplasma infec-tions relies on the inhibition of folate metabolism. The proto-
col recommends synergistic combination of diaminopyrimidines
with sulfonamides, supplemented with folinic acid tomitigate the
toxic effects of pyrimethamine on bonemarrow. For patients with
sensitivity to sulfonamines, macrolides and lincosamides are a
second class of medications with anti-Toxoplasma activity. The
third class of anti-Toxoplasma drugs, which are only occasionally
used as a potential substitute, comprises electron transport inhib-
itors such as atovaquone (1). In all of these situations, drug resis-
tance, high cost, limited efficacy, and side effects of these drugs
often result in discontinuation of therapy (2–5). Therefore, new
agents with better activity profiles and that are less expensive are
needed. One possible class of drugs are s-triazole derivatives, and
in this article, we present a newly found triazole-based candidate
to develop novel medicines for more effective treatment of toxo-
plasmosis.
The search for agents that are potent and selective against Tox-
oplasma continues in several laboratories. Numerous inhibitors
with activities in the nanomolar range with no appreciable in vitro
toxicity to human cells have been identified. Examples are pyrim-
idines, oryzalines, thiazolidinones, berberines, tryptanthrines,
thiocyanates, and bisphosphonates (6, 7). Our attention has been
focused on the role of s-triazole series as potential new toxoplas-
mosis therapeutics. We found that 3-(thiophen-2-yl)-1,2,4-tria-
zole-5-thione (compound 1) showed a potent and reproducible
antiparasitic effect with no appreciable toxicity to human cells,
while 4-ethyl-3-(4-methyl-1,2,3-thiadiazol-5-yl)-1,2,4-triazole-
5-thione (compound 2) was inactive.
The procedure for synthesis of 3-(thiophen-2-yl)-1,2,4-tria-
zole-5-thione (compound 1) and 4-ethyl-3-(4-methyl-1,2,3-thia-
diazol-5-yl)-1,2,4-triazole-5-thione (compound 2), the effects of
tested compounds and sulfadiazine on the viability of L929
(ATCC no. CCL-1) and HeLa (ATCC no. CCL-2) cells, and inhi-
bition of Toxoplasma (RH strain; ATCC no. 50174) growth were
described elsewhere (8). The effect of tested compounds on the
intensity of Toxoplasma gondii proliferation (%) wasmeasured by
2 methods: incorporation of [3H]uracil (Fig. 1) into the T. gondii
DNA (9) and quantitative real-time PCR (qRT-PCR) (Fig. 1) (8).
The 50% inhibitory concentration (IC50 [g/ml]) represents the
concentration of tested compounds that was required for inhibi-
tion of 50% of T. gondii proliferation on the cell lines used. The
cytotoxic effect of the tested compound on the mouse L929 fibro-
blasts (percentage of viable cells) (Fig. 2) was measured using
the MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide] assay according to the international standard
ISO 10993-5:2009(E). To calculate the reduction of cell viability
compared to viability in the untreated blank, the following equa-
tion was used: % viability 100 (sample OD570/blank OD570),
where sample OD570 is the mean value of the measured optical
density at 570 nm of the tested samples and “blank OD570” is the
mean value of themeasuredOD570 of the untreated cells. The 30%
cytotoxic concentration (CC30 [g/ml]) represents the concen-
tration of tested compounds that was required for a 30% cytotoxic
effect of the tested compounds on L929 cells. Selectivity refers to
the ratio of the CC50 value for L929 fibroblasts to the IC50 for T.
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FIG 1 Intensity ofT. gondiiproliferation (percentage) on the L929 host cells in
the presence of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione (Œ and) and sul-
fadiazine ( and ) with determined IC50s by 2 methods: incorporation of
3[H]uracil (Œ and ) and qRT-PCR ( and ).
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gondii RH measured by incorporation of [3H]uracil (Fig. 2, I) or
the qRT-PCR (Fig. 2, II) assay. CC30 and IC50 values were deter-
mined based on the plotted curves using GraphPad Prism pro-
gram (version 6.04). The results of the experiments are shown as
mean arithmetic values from 6 to 18 repeats (2 to 6 experiments).
The FlexX program was used as implemented in the LeadIT soft-
ware package. The receptor for FlexX was prepared using the de-
fault setting, and the details are described in reference 8.
To assess inhibition of RH strain growth in vitro, tachyzoites
were cultured with various concentrations of the s-triazole (com-
pound 1) ranging from 1 to 500g/ml. Parasite growth inhibition
in L929 cells by compound 1 and the control drug, sulfadiazine,
together with the IC50s is shown in Fig. 1. As can be seen, com-
pound 1 showed a statistically significant antiparasitic effect by the
IC50 (42.46 or 37.33 g/ml), which was at least 32.6-fold lower
than the one observed for sulfadiazine (2,225.24 or 1,217.62 g/
ml), depending on which method was used for measuring the
intensity of parasite proliferation ([3H]uracil incorporation or
qRT-PCR, respectively). In the case of the HeLa cells, the IC50
(58.5 g/ml) was also lower (30.6-fold) than that with IC50
(1,790.0 g/ml) for sulfadiazine using the [3H]uracil incorpora-
tion assay. Compound 1 showed evident anti-Toxoplasma activity
and exhibited more than 4 greater selectivity than sulfadiazine
(Fig. 2). It should be mentioned that the drug susceptibility of the
sulfadiazine-nonresistant RH strain depends on the host cells
used. The determined IC50s varied from 2.5 to 70 g/ml for nor-
mal cell lines (MRC-5, HFF, and Vero) and from 600 to 1,724
g/ml for the carcinoma Hep-2 and HeLa cell lines (10–12).
Since the ideal antiparasitic agent would have no toxic or low-
toxicity effects on host cells, the effect of compound 1 in terms of
its ability to inhibit the growth of mouse fibroblasts (Fig. 2) and
human cervical cancer cell lines was also explored (data not
shown). Toxicity was defined as the highest dilution of test sam-
ples that causes 30% or greater destruction of cells. From a com-
parison of the results on toxicity and anti-T. gondii activity tests, it
can be clearly seen that compound 1 inhibited the parasite growth
at noncytotoxic concentrations for host cells.
The last part of our study was dedicated to understanding the
molecular basis of inhibitory potency of compound 1 againstTox-
oplasma. The literature search identified six enzymes as reasonable
targets for discovering anti-Toxoplasma agents: i.e., 3MB8 (purine
nucleoside phosphorylase) (13), 1LII (adenosine kinase (14),
DHRF (dihydrofolate reductase) (15), 4M84 (calmodulin-do-
main protein kinase 1) (16), 3AU9 (1-deoxy-D-xylulose-5-phos-
phate reductoisomerase) (17), and 2O2S (enoyl-acyl carrier re-
ductase) (18). Based on the structures deposited in the Protein
Data Bank, we analyzed the binding affinities of the active com-
pound 1 and inactive compound 2 s-triazoles to the active sites of
the aforementioned enzymes. We have excluded the model of the
dihydrofolate reductase binding site (PDB ID no. 4EIL) because
this enzyme is also present in humans, so treatment with DHRF
inhibitors may induce a folate deficiency, which is possibly re-
sponsible for severe hematological pathologies and embryopa-
thies. The largest difference in docking score has been observed for
the enzyme model 3AU9, followed by 4M84 and 3MB8 (Fig. 3).
Given the difference in bioactivities of compounds 1 and 2, these
three enzymes seem to be potential targets. In all cases, the appar-
ent main source of the differentiation is the size exclusion; active
sites are tight and deeply buried in the protein, making access for
the bulkier compound much harder or impossible. In fact, the
active site is so tight in the case of 3AU9 that it was not possible to
dock inactive s-triazole (compound 2) using the “hard” docking
protocol, and only after loosening the “maximumallowed overlap
volume” to100 Å3 (i.e., “soft” docking) did it become possible
(Fig. 3). Nearly no preference in binding to the active site was
observed in case of 1LII, while in case of 2O2S, the docking pref-
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FIG 2 Cytotoxic effect of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione (Œ) and
sulfadiazine () on L929 mouse fibroblasts compared to selectivity (CC30/
IC50) for both s-triazole and sulfadiazine by 2 methods: incorporation of
3[H]uracil (I) and qRT-PCR (II).
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FIG 3 Scores of top poses of compounds 1 and 2 docked to different proteins: 3AU9 (1-deoxy-D-xylulose 5-phosphate reductoisomerase), 4M84 (calmodulin-
domain protein kinase 1), 3MB8 (purine nucleoside phosphorylase), 1LII (adenosine kinase), 2O2S (enoyl-acyl carrier reductase). *, results in parentheses are
for the soft docking conditions (see the text). Shown is a schematic representation of interactions of compound 1 in the active site of 1-deoxy-D-xylulose
5-phosphate reductoisomerase and the binding cavity with the active site superimposed on the native ligand.
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erence is reversed, with strong binding of the inactive s-triazole
(compound 2), which was in clear disagreement with experimen-
tal observations. Out of the chosen three proteins, the strongest
binding is expected for 3AU9, and this enzyme seems to be the
most probable target. The binding mode of the active ligand
(compound 1) in its active site is illustrated in Fig. 3.
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